• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Indivior PLC

    10/17/24 2:53:58 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INDV alert in real time by email
    SC 13D/A 1 form_sc13da-indivior.htm

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     
    _________________________________________________________

    SCHEDULE 13D
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)*
     
    _________________________________________________________

    INDIVIOR PLC
    (Name of Issuer)
    Ordinary Shares, $0.50 nominal value per share
    (Title and Class of Securities)
    G4766E116
    (CUSIP Number)
    Lawrence V. Palermo
    Two Seas Capital LP
    32 Elm Place, 3rd Floor
    Rye, NY 10580
    (646) 420-4504
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    October 15, 2024
    (Date of Event Which Requires Filing of Statement)
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box.  [  ]

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.
     
    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)
     

    Schedule 13D
     CUSIP No. G4766E116
     
     
     
                 
      (1) 
     
    Name of Reporting Persons:
     
    Two Seas Capital LP
      (2)
     
    Check the Appropriate Box if a Member of a Group (See Instructions):
    (a)  ☐        (b)  ☐
     
      (3)
     
    SEC Use Only:
     
      (4)
     
    Source of Funds (See Instructions):
     
    AF
      (5)
     
    Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):  ☐
     
      (6)
     
    Citizenship or Place of Organization:
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
     
      
      (7) 
      
    Sole Voting Power
     
    13,030,027
      
      (8)
      
    Shared Voting Power
     
    0
      
      (9)
      
    Sole Dispositive Power
     
    13,030,027
      
    (10)
      
    Shared Dispositive Power
     
    0
    (11)
     
    Aggregate Amount Beneficially Owned by Each Reporting Person:
     
    13,030,027
    (12)
     
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):  ☐
     
    (13)
     
    Percent of Class Represented by Amount in Row (11):
     
    10.1% (1)
    (14)
     
    Type of Reporting Person (See Instructions):
     
    PN, IA
     
    (1)
     Based on 128,588,498 Ordinary Shares of Indivior PLC (the “Issuer”) outstanding as of October 14, 2024, as reported in the Issuer’s Form 6-K filed with the Securities and Exchange Commission (“SEC”) on October 15, 2024.


    Schedule 13D
    CUSIP No. G4766E116
     
     

                 
      (1) 
     
    Name of Reporting Persons:
     
    Two Seas Capital GP LLC
      (2)
     
    Check the Appropriate Box if a Member of a Group (See Instructions):
    (a)  ☐        (b)  ☐
     
      (3)
     
    SEC Use Only:
     
      (4)
     
    Source of Funds (See Instructions):
     
    AF
      (5)
     
    Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):  ☐
     
      (6)
     
    Citizenship or Place of Organization:
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
     
      
      (7) 
      
    Sole Voting Power
     
    13,030,027
      
      (8)
      
    Shared Voting Power
     
    0
      
      (9)
      
    Sole Dispositive Power
     
    13,030,027
      
    (10)
      
    Shared Dispositive Power
     
    0
    (11)
     
    Aggregate Amount Beneficially Owned by Each Reporting Person:
     
    13,030,027
    (12)
     
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):  ☐
     
    (13)
     
    Percent of Class Represented by Amount in Row (11):
     
    10.1% (1)
    (14)
     
    Type of Reporting Person (See Instructions):
     
    OO, HC
     
    (1)
     Based on 128,588,498 Ordinary Shares of the Issuer outstanding as of October 14, 2024, as reported in the Issuer’s Form 6-K filed with the SEC on October 15, 2024.




    Schedule 13D
     
    CUSIP No. G4766E116
     
     
     
                 
      (1) 
     
    Name of Reporting Persons:
     
    Sina Toussi
      (2)
     
    Check the Appropriate Box if a Member of a Group (See Instructions):
    (a)  ☐        (b)  ☐
     
      (3)
     
    SEC Use Only:
     
      (4)
     
    Source of Funds (See Instructions):
     
    AF
      (5)
     
    Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):  ☐
     
      (6)
     
    Citizenship or Place of Organization:
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
     
      
      (7) 
      
    Sole Voting Power
     
    13,030,027
      
      (8)
      
    Shared Voting Power
     
    0
      
      (9)
      
    Sole Dispositive Power
     
    13,030,027
      
    (10)
      
    Shared Dispositive Power
     
    0
    (11)
     
    Aggregate Amount Beneficially Owned by Each Reporting Person:
     
    13,030,027
    (12)
     
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):  ☐
     
    (13)
     
    Percent of Class Represented by Amount in Row (11):
     
    10.1% (1)
    (14)
     
    Type of Reporting Person (See Instructions):
     
    HC, IN
     
    (1)
    Based on 128,588,498 Ordinary Shares of the Issuer outstanding as of October 14, 2024, as reported in the Issuer’s Form 6-K filed with the SEC on October 15, 2024.




    AMENDMENT NO. 3 TO SCHEDULE 13D

    The following constitutes Amendment No. 3 (“Amendment No. 3”) to the Schedule 13D filed with the Securities and Exchange Commission (“SEC”) by Two Seas Capital LP (“TSC”), Two Seas Capital GP LLC (“TSC GP”) and Sina Toussi on October 2, 2023, as amended by Amendment No. 1 filed on March 29, 2024, and Amendment No. 2 filed on June 21, 2024.  This Amendment No. 3 amends and supplements the Schedule 13D as specifically set forth herein.

    All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D, as amended. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.
     
    ITEM 3.
    SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

    Item 3 of the Schedule 13D is hereby amended and restated as follows:

    The aggregate purchase price of the 10,899,480 Ordinary Shares directly held by the Litigation Fund reported herein was approximately $95,960,755. The aggregate purchase price of the 2,130,547 Ordinary Shares directly held by the Global Fund reported herein was approximately $25,632,796. The Ordinary Shares directly held by the Funds were purchased with the working capital of the Funds (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business) and proceeds from the Credit Facility (the “Credit Facility”) for the Litigation Fund, provided by UBS AG, London Branch (“UBS”), pursuant to the Credit Facility Agreement, by and between, the Litigation Fund, as Borrower, and UBS, acting as Lender, dated June 16, 2022, as amended and restated on September 22, 2022, on April 5, 2023, and on June 19, 2023, as amended on December 20, 2023, and as amended and restated by the Fifth Amendment Agreement, dated June 20, 2024 (the “Credit Facility Agreement”).

    ITEM 5.
    INTEREST IN SECURITIES OF THE ISSUER

    Item 5 of the Schedule 13D is hereby amended and restated as follows:

    (a) and (b) Items 7 through 11 and 13 of each of the cover pages of this Schedule 13D are incorporated herein by reference. Such information is based on 128,588,498 Ordinary Shares of the Issuer outstanding as of October 14, 2024, as reported in the Issuer’s Form 6-K filed with the Securities and Exchange Commission on October 15, 2024. The information in Item 3 regarding the number of Ordinary Shares held by the Funds is incorporated herein by reference.

    The Funds have delegated to TSC sole voting and investment power over the securities held by the Funds pursuant to their respective Investment Management Agreements with TSC. As a result, each of TSC, TSC GP, as the general partner of TSC, and Mr. Toussi, as Chief Investment Officer of TSC and Managing Member of TSC GP, may be deemed to exercise voting and investment power over the Ordinary Shares directly held by the Funds. The Funds specifically disclaim beneficial ownership of the securities of the Issuer directly held by them by virtue of their inability to vote or dispose of such securities as a result of their respective Investment Management Agreements with TSC.

    (c) The Reporting Persons have not effected any transactions in the Ordinary Shares of the Issuer during the past 60 days.

    (d) The disclosure regarding the relationship between the Reporting Persons in Item 2(c) of this Schedule 13D is incorporated herein by reference. All securities reported in this Schedule 13D are directly held by the Funds, each of which are investment management clients of TSC. The limited partners of (or investors in) each of the Funds have the right to participate in the receipt of dividends from, or proceeds from the sale of, the Ordinary Shares held for the accounts of their respective Funds in accordance with their respective limited partnership interests (or investment percentages) in their respective Funds.

    (e) Not applicable.

    ITEM 6.
    CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

    Item 6 of this Schedule 13D is supplemented and superseded, as the case may be, as follows:

    On October 15, 2024, the Litigation Fund paid $23,834,213.11 to UBS to reduce the amount owed by the Litigation Fund to UBS under the Credit Facility.

    Pursuant to the Security Agreement, dated June 16, 2022, by and between the Litigation Fund, as Grantor, and UBS, as Secured Party, as amended (the “Security Agreement”), the Litigation Fund has pledged to UBS 10,899,480 Ordinary Shares held by it, subject to potential adjustments agreed upon by the parties from time to time. If the Litigation Fund defaults on its obligations under the Credit Facility Agreement, such default could result in foreclosure proceedings against the Ordinary Shares pledged as collateral by the Litigation Fund, subject to a beneficial ownership limitation.  The pledged Ordinary Shares are subject to certain transfer restrictions.  The total commitment under the Credit Facility was fully drawn and a loan amount of $18,774,884.89 that was drawn remains outstanding, subject to potential adjustments agreed upon by the parties from time to time. The Credit Facility is subject to typical credit terms and certain event of default triggers, some of which may be satisfied by unencumbered assets of the Litigation Fund. The maturity date for the Credit Facility is July 31, 2025, and the interest rate under the Credit Facility is a variable rate plus a reference rate.  The Global Fund has no potential encumbrances with respect to the Credit Facility.



    The Global Fund has entered into cash-settled swaps which represent economic exposure comparable to a notional interest in 1,489,081 Ordinary Shares (representing economic exposure comparable to approximately 1.2% of the outstanding Ordinary Shares) with Jefferies Financial Products, LLC and cash-settled swaps which represent economic exposure comparable to a notional interest in 811,421 Ordinary Shares (representing economic exposure comparable to approximately 0.6% of the outstanding Ordinary Shares) with Goldman Sachs International.  Under the terms of the swaps, (i) the Global Fund will be obligated to pay to the counterparty any negative price performance of the specified notional number of Ordinary Shares subject to the swaps as of the expiration date of such swaps, plus interest rates set forth in the applicable contracts, and (ii) the counterparty will be obligated to pay the Global Fund any positive price performance of the specified notional number of Ordinary Shares subject to the swaps as of the expiration date of the swaps.  All balances will be settled in cash. The swaps do not give the Reporting Persons or Funds direct or indirect voting, investment or dispositive control over any securities of the Issuer and do not require the counterparty thereto to acquire, hold, vote or dispose of any securities of the Issuer.  Accordingly, the Reporting Persons disclaim any beneficial ownership of any Ordinary Shares that may be referenced in the swap contracts or Ordinary Shares or other securities or financial instruments that may be held from time to time by any counterparty to the contracts.


    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
    Dated as of October 17, 2024
     
           
     
    TWO SEAS CAPITAL LP
         
     
    By:
     
    Two Seas Capital GP LLC, its general partner
         
     
    By:
     
    /s/ Sina Toussi
     
    Name:
     
    Sina Toussi
     
    Title:
     
    Managing Member
       
     
    TWO SEAS CAPITAL GP LLC
         
     
    By:
     
    /s/ Sina Toussi
     
    Name:
     
    Sina Toussi
     
    Title:
     
    Managing Member
     
     
    SINA TOUSSI
         
     
    By:
     
    /s/ Sina Toussi


    Get the next $INDV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INDV

    DatePrice TargetRatingAnalyst
    1/28/2025$16.00Buy
    Rodman & Renshaw
    7/23/2024$22.00Overweight
    Piper Sandler
    4/3/2024$37.00Buy
    Craig Hallum
    7/13/2023$35.00Outperform
    Northland Capital
    More analyst ratings

    $INDV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Indivior PLC

      SC 13G - INDIVIOR PLC (0001625297) (Subject)

      11/15/24 6:03:54 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Indivior PLC

      SC 13G/A - INDIVIOR PLC (0001625297) (Subject)

      11/14/24 5:00:25 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Indivior PLC

      SC 13D/A - INDIVIOR PLC (0001625297) (Subject)

      11/7/24 8:23:16 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Indivior with a new price target

      Rodman & Renshaw initiated coverage of Indivior with a rating of Buy and set a new price target of $16.00

      1/28/25 7:14:13 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Indivior with a new price target

      Piper Sandler initiated coverage of Indivior with a rating of Overweight and set a new price target of $22.00

      7/23/24 6:29:18 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Craig Hallum initiated coverage on Indivior with a new price target

      Craig Hallum initiated coverage of Indivior with a rating of Buy and set a new price target of $37.00

      4/3/24 7:45:35 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

      SLOUGH, England and RICHMOND, Va., June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List (the "Official List") of the U.K. Financial Conduct Authority ("FCA"); and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's ("LSE") main market for listed securities (together, the "London Delisting"). Background to and Reasons for the London Delisting In the circula

      6/2/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces Patrick Barry as Chief Commercial Officer

      Seasoned commercial executive with more than 30 years of pharmaceutical experience RICHMOND, Va., May 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2. In this role, Barry will lead the company's commercial growth strategy, execution, and operations as Indivior continues its mission to transform the treatment of opioid use disorder led by SUBLOCADE® (buprenorphine extended-release) Injection. Barry will join Indivior's executive committee. "Patrick is an accomplished and resp

      5/27/25 8:30:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior to Participate in Upcoming Investor Events

      RICHMOND, Va., May 13, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ/LSE: INDV) today announced that it will participate in the following investor events: Jefferies Global Healthcare Conference – New York City, NYJoe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Wednesday, June 4th. Joe Ciaffoni will also participate in a fireside discussion on Wednesday, June 4th at 9:55 a.m. U.S. ET. Interested investors should contact their Jefferies representative to schedule a meeting. The fireside discussion will be publicly

      5/13/25 10:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Leadership Updates

    Live Leadership Updates

    See more
    • Indivior Announces Patrick Barry as Chief Commercial Officer

      Seasoned commercial executive with more than 30 years of pharmaceutical experience RICHMOND, Va., May 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2. In this role, Barry will lead the company's commercial growth strategy, execution, and operations as Indivior continues its mission to transform the treatment of opioid use disorder led by SUBLOCADE® (buprenorphine extended-release) Injection. Barry will join Indivior's executive committee. "Patrick is an accomplished and resp

      5/27/25 8:30:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces Further Changes to Board of Directors

      RICHMOND, Va., March 4, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) ("Indivior" or the "Company") today announced that, further to the announcement on December 17, 2024 of certain Director arrangements agreed with Oaktree Capital Management L.P. ("Oaktree"), the announcement on January 28, 2025 of the appointment of Dr. David Wheadon as Chair of the Company, the announcement on February 3, 2025 of the appointment of Daniel Ninivaggi as an Independent Non-Executive Director of the Company, and the announcement on February 27, 2025 of the appointment of Joe Ciaffoni as Chief Executive Officer of the Company, and following further discussions with Oaktree, the Company has agreed to m

      3/4/25 8:40:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Financials

    Live finance-specific insights

    See more
    • Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

      SLOUGH, England and RICHMOND, Va., June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List (the "Official List") of the U.K. Financial Conduct Authority ("FCA"); and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's ("LSE") main market for listed securities (together, the "London Delisting"). Background to and Reasons for the London Delisting In the circula

      6/2/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces Q1 2025 Financial Results

      SLOUGH, United Kingdom and RICHMOND, Va., April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.com

      4/24/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces FY and Q4 2024 Financial Results

      SLOUGH, United Kingdom and RICHMOND, Va., Feb. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending December 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.c

      2/20/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    SEC Filings

    See more
    • SEC Form 8-K filed by Indivior PLC

      8-K - INDIVIOR PLC (0001625297) (Filer)

      6/2/25 6:06:09 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior PLC filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - INDIVIOR PLC (0001625297) (Filer)

      5/30/25 6:51:16 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Indivior PLC

      SCHEDULE 13D/A - INDIVIOR PLC (0001625297) (Subject)

      5/22/25 4:45:47 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care